GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
last added cars
2023-04-11|

Sobi Enters Into New Royalty Agreement on RSV Antibody Drug Nirsevimab With Sanofi

by Richard Chau
Share To

Headquartered in Stockholm, Sweden, Swedish Orphan Biovitrum AB (Sobi) has announced the streamlining and simplification of contractual agreements for nirsevimab (Beyfortus), an antibody drug treating respiratory syncytial virus (RSV) in infants.

Sobi has entered into a new royalty agreement with Sanofi, in which the Swedish biopharma company will pay the French side $66 million as reimbursement for the expenses incurred in the research and development of nirsevimab in the United States.

Related article: AstraZeneca, Sanofi’s RSV Antibody Recommended For Approval In EU

Nirsevimab Protects Against RSV in Infants

Human RSV is one of the most common viruses to infect children worldwide and nearly all children will experience at least one RSV infection before the age of 2, causing symptoms that resemble a common cold. However, in some rare and severe cases, the virus may spread to the lower respiratory tract, causing life-threatening lower respiratory tract infection (LRTI) such as pneumonia or bronchiolitis.

With the aim of protecting infants, children other high-risk individuals from this highly contagious virus, several big pharmaceutical companies are in heated competition for the first FDA-approved RSV vaccine. Besides, the development of novel antiviral treatments for RSV is also underway. Examples include palivizumab (Synagis), a humanized monoclonal antibody (mAb) as an FDA-approved drug for RSV immunoprophylaxis for severe RSV-associated LRTI in high-risk pediatric populations. Another example is nirsevimab which appears in the latest agreement between Sobi and Sanofi. It is a single dose, long-acting mAb under development as a passive immunization for LRTI caused by RSV for children up to 24 months of age.

Nirsevimab was initially developed and commercialized in partnership by AstraZeneca and Sanofi. The drug won EU approval for the above-mentioned indication in November 2022. Also, the U.S. FDA accepted AstraZeneca’s Biologics License Application (BLA) for Nirsevimab for review in January, with the final decision to be announced in the third quarter. In January 2019, Sobi obtained the rights to participate in 50% of the U.S. profits of Nirsevimab together with the acquisition of Synagis by paying AstraZeneca $1.5 billion upfront.

Simplifying and Streamlining the Relationships With the Pharma Giants

According to the newly signed royalty agreement with Sanofi, Sobi will receive a quarterly royalty on net sales of nirsevimab in the US. Royalty rates will start at 25% at launch anticipated in 2023, continue in 2024 and increase each year from 2025 to 2028 in a tiered fashion to a range of 30 to 35% of net sales. Beyond 2028, royalty rates will remain at these levels.

Through a separate agreement with AstraZeneca, Sobi will pay AstraZeneca $15 million as an upfront final consideration, terminating the 2019 participation agreement related to nirsevimab. This termination removes Sobi’s right to AstraZeneca’s share of US profits and losses for nirsevimab, including US development and commercialization costs and the obligation to pay future milestones and royalties to AstraZeneca.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Pre-JPM 2025: The Quiet Deals You May Have Missed Before the Big Show
2025-01-16
AstraZeneca & Daiichi Sankyo Voluntarily Withdraw EU Submission for Lung Cancer Drug
2024-12-26
R&D
Teva and Sanofi’s Best-in-Class IBD Drug a Game-Changer in the Antibody Therapeutics Arena
2024-12-18
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
Scroll to Top